Skip to main content
PMC home page
Gut logoLink to Gut
. 1998 May;42(5):599–602. doi: 10.1136/gut.42.5.599

The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis

I McFARLANE 1
PMCID: PMC1727103  PMID: 9659147

Full Text

The Full Text of this article is available as a PDF (79.0 KB).

Figure 1 .

Figure 1

Open in a new tab

Distribution according to age at presentation and HLA DR3 and DR4 status of 118 adults with autoimmune hepatitis attending the Institute of Liver Studies, King's College Hospital, London, UK.


Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abuaf N., Johanet C., Chretien P., Martini E., Soulier E., Laperche S., Homberg J. C. Characterization of the liver cytosol antigen type 1 reacting with autoantibodies in chronic active hepatitis. Hepatology. 1992 Oct;16(4):892–898. doi: 10.1002/hep.1840160407. [DOI] [PubMed] [Google Scholar]
  2. Bayraktar Y., Bayraktar M., Gurakar A., Hassanein T. I., Van Thiel D. H. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases. Hepatogastroenterology. 1997 Mar-Apr;44(14):417–425. [PubMed] [Google Scholar]
  3. Cançado E. L., Vilas-Boas L. S., Abrantes-Lemos C. P., Novo N. F., Porta G., Da Silva L. C., Laudanna A. A. Heat serum inactivation as a mandatory procedure for antiactin antibody detection in cell culture. Hepatology. 1996 May;23(5):1098–1104. doi: 10.1002/hep.510230525. [DOI] [PubMed] [Google Scholar]
  4. Cassani F., Cataleta M., Valentini P., Muratori P., Giostra F., Francesconi R., Muratori L., Lenzi M., Bianchi G., Zauli D. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology. 1997 Sep;26(3):561–566. doi: 10.1002/hep.510260305. [DOI] [PubMed] [Google Scholar]
  5. Czaja A. J., Carpenter H. A., Manns M. P. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology. 1993 Nov;105(5):1522–1528. doi: 10.1016/0016-5085(93)90160-e. [DOI] [PubMed] [Google Scholar]
  6. Czaja A. J., Carpenter H. A., Santrach P. J., Moore S. B., Taswell H. F., Homburger H. A. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol. 1993 Jul;18(3):342–352. doi: 10.1016/s0168-8278(05)80279-x. [DOI] [PubMed] [Google Scholar]
  7. Czaja A. J., Cassani F., Cataleta M., Valentini P., Bianchi F. B. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci. 1997 Aug;42(8):1688–1696. doi: 10.1023/a:1018809431189. [DOI] [PubMed] [Google Scholar]
  8. Czaja A. J., Cassani F., Cataleta M., Valentini P., Bianchi F. B. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology. 1996 Nov;24(5):1068–1073. doi: 10.1002/hep.510240515. [DOI] [PubMed] [Google Scholar]
  9. Czaja A. J., Hay J. E., Rakela J. Clinical features and prognostic implications of severe corticosteroid-treated cryptogenic chronic active hepatitis. Mayo Clin Proc. 1990 Jan;65(1):23–30. doi: 10.1016/s0025-6196(12)62106-5. [DOI] [PubMed] [Google Scholar]
  10. Czaja A. J., Manns M. P., Homburger H. A. Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology. 1992 Oct;103(4):1290–1295. doi: 10.1016/0016-5085(92)91518-9. [DOI] [PubMed] [Google Scholar]
  11. Czaja A. J., Manns M. P. The validity and importance of subtypes in autoimmune hepatitis: a point of view. Am J Gastroenterol. 1995 Aug;90(8):1206–1211. [PubMed] [Google Scholar]
  12. Czaja A. J., Strettell M. D., Thomson L. J., Santrach P. J., Moore S. B., Donaldson P. T., Williams R. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997 Feb;25(2):317–323. doi: 10.1002/hep.510250211. [DOI] [PubMed] [Google Scholar]
  13. Desmet V. J., Gerber M., Hoofnagle J. H., Manns M., Scheuer P. J. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994 Jun;19(6):1513–1520. [PubMed] [Google Scholar]
  14. Dighiero G., Lymberi P., Monot C., Abuaf N. Sera with high levels of anti-smooth muscle and anti-mitochondrial antibodies frequently bind to cytoskeleton proteins. Clin Exp Immunol. 1990 Oct;82(1):52–56. doi: 10.1111/j.1365-2249.1990.tb05402.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Doherty D. G., Donaldson P. T., Underhill J. A., Farrant J. M., Duthie A., Mieli-Vergani G., McFarlane I. G., Johnson P. J., Eddleston A. L., Mowat A. P. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology. 1994 Mar;19(3):609–615. doi: 10.1002/hep.1840190311. [DOI] [PubMed] [Google Scholar]
  16. Doherty D. G., Underhill J. A., Donaldson P. T., Manabe K., Mieli-Vergani G., Eddleston A. L., Vergani D., Demaine A. G., Williams R. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity. 1994;18(4):243–249. doi: 10.3109/08916939409009525. [DOI] [PubMed] [Google Scholar]
  17. Donaldson P. T., Doherty D. G., Hayllar K. M., McFarlane I. G., Johnson P. J., Williams R. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991 Apr;13(4):701–706. [PubMed] [Google Scholar]
  18. Esteban J. I., Esteban R., Viladomiu L., López-Talavera J. C., González A., Hernández J. M., Roget M., Vargas V., Genescà J., Buti M. Hepatitis C virus antibodies among risk groups in Spain. Lancet. 1989 Aug 5;2(8658):294–297. doi: 10.1016/s0140-6736(89)90485-6. [DOI] [PubMed] [Google Scholar]
  19. Han S., Tredger M., Gregorio G. V., Mieli-Vergani G., Vergani D. Anti-liver cytosolic antigen type 1 (LC1) antibodies in childhood autoimmune liver disease. Hepatology. 1995 Jan;21(1):58–62. [PubMed] [Google Scholar]
  20. Homberg J. C., Abuaf N., Bernard O., Islam S., Alvarez F., Khalil S. H., Poupon R., Darnis F., Lévy V. G., Grippon P. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology. 1987 Nov-Dec;7(6):1333–1339. doi: 10.1002/hep.1840070626. [DOI] [PubMed] [Google Scholar]
  21. Johnson P. J., McFarlane I. G., McFarlane B. M., Williams R. Auto-immune features in patients with idiopathic chronic active hepatitis who are seronegative for conventional auto-antibodies. J Gastroenterol Hepatol. 1990 May-Jun;5(3):244–251. doi: 10.1111/j.1440-1746.1990.tb01624.x. [DOI] [PubMed] [Google Scholar]
  22. Johnson P. J., McFarlane I. G. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993 Oct;18(4):998–1005. doi: 10.1002/hep.1840180435. [DOI] [PubMed] [Google Scholar]
  23. Kaymakoglu S., Cakaloglu Y., Demir K., Türkoglu S., Badur S., Gürel S., Beşişik F., Cevikbaş U., Okten A. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol. 1998 Jan;28(1):78–83. doi: 10.1016/s0168-8278(98)80205-5. [DOI] [PubMed] [Google Scholar]
  24. Leibovitch L., George J., Levi Y., Bakimer R., Shoenfeld Y. Anti-actin antibodies in sera from patients with autoimmune liver diseases and patients with carcinomas by ELISA. Immunol Lett. 1995 Dec;48(2):129–132. doi: 10.1016/0165-2478(95)02456-5. [DOI] [PubMed] [Google Scholar]
  25. Lenzi M., Ballardini G., Fusconi M., Cassani F., Selleri L., Volta U., Zauli D., Bianchi F. B. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet. 1990 Feb 3;335(8684):258–259. doi: 10.1016/0140-6736(90)90070-l. [DOI] [PubMed] [Google Scholar]
  26. Lenzi M., Johnson P. J., McFarlane I. G., Ballardini G., Smith H. M., McFarlane B. M., Bridger C., Vergani D., Bianchi F. B., Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 1991 Aug 3;338(8762):277–280. doi: 10.1016/0140-6736(91)90418-o. [DOI] [PubMed] [Google Scholar]
  27. Lenzi M., Manotti P., Muratori L., Cataleta M., Ballardini G., Cassani F., Bianchi F. B. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection. Gut. 1995 May;36(5):749–754. doi: 10.1136/gut.36.5.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lindgren S., Braun H. B., Michel G., Nemeth A., Nilsson S., Thome-Kromer B., Eriksson S. Absence of LKM-1 antibody reactivity in autoimmune and hepatitis-C-related chronic liver disease in Sweden. Swedish Internal Medicine Liver club. Scand J Gastroenterol. 1997 Feb;32(2):175–178. doi: 10.3109/00365529709000189. [DOI] [PubMed] [Google Scholar]
  29. Lunel F., Abuaf N., Frangeul L., Grippon P., Perrin M., Le Coz Y., Valla D., Borotto E., Yamamoto A. M., Huraux J. M. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology. 1992 Sep;16(3):630–636. doi: 10.1002/hep.1840160304. [DOI] [PubMed] [Google Scholar]
  30. Mackay I. R., Tait B. D. HLA associations with autoimmune-type chronic active hepatitis: identification of B8-DRw3 haplotype by family studies. Gastroenterology. 1980 Jul;79(1):95–98. [PubMed] [Google Scholar]
  31. Maddrey W. C. How many types of autoimmune hepatitis are there? Gastroenterology. 1993 Nov;105(5):1571–1575. doi: 10.1016/0016-5085(93)90170-h. [DOI] [PubMed] [Google Scholar]
  32. Manns M. P. Cytoplasmic autoantigens in autoimmune hepatitis: molecular analysis and clinical relevance. Semin Liver Dis. 1991 Aug;11(3):205–214. doi: 10.1055/s-2008-1040438. [DOI] [PubMed] [Google Scholar]
  33. Manns M. P., Krüger M. Immunogenetics of chronic liver diseases. Gastroenterology. 1994 Jun;106(6):1676–1697. doi: 10.1016/0016-5085(94)90427-8. [DOI] [PubMed] [Google Scholar]
  34. Manns M., Gerken G., Kyriatsoulis A., Staritz M., Meyer zum Büschenfelde K. H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet. 1987 Feb 7;1(8528):292–294. doi: 10.1016/s0140-6736(87)92024-1. [DOI] [PubMed] [Google Scholar]
  35. Martini E., Abuaf N., Cavalli F., Durand V., Johanet C., Homberg J. C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology. 1988 Nov-Dec;8(6):1662–1666. doi: 10.1002/hep.1840080632. [DOI] [PubMed] [Google Scholar]
  36. McFarlane I. G. Autoimmunity and hepatotropic viruses. Semin Liver Dis. 1991 Aug;11(3):223–233. doi: 10.1055/s-2008-1040440. [DOI] [PubMed] [Google Scholar]
  37. Muratori L., Lenzi M., Ma Y., Cataleta M., Mieli-Vergani G., Vergani D., Bianchi F. B. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut. 1995 Sep;37(3):406–412. doi: 10.1136/gut.37.3.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Scully L. J., Toze C., Sengar D. P., Goldstein R. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology. 1993 May;104(5):1478–1484. doi: 10.1016/0016-5085(93)90359-k. [DOI] [PubMed] [Google Scholar]
  39. Stechemesser E., Klein R., Berg P. A. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology. 1993 Jul;18(1):1–9. [PubMed] [Google Scholar]
  40. Strettell M. D., Donaldson P. T., Thomson L. J., Santrach P. J., Moore S. B., Czaja A. J., Williams R. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997 Jun;112(6):2028–2035. doi: 10.1053/gast.1997.v112.pm9178696. [DOI] [PubMed] [Google Scholar]
  41. Takaki A., Sakaguchi K., Ogawa S., Kawamoto H., Tsuji T. Specificities and clinical significance of anti-cytoskeleton antibodies in anti-smooth muscle antibody-positive patients with chronic liver disease C. Acta Med Okayama. 1994 Jun;48(3):143–149. doi: 10.18926/AMO/31129. [DOI] [PubMed] [Google Scholar]
  42. Targan S. R., Landers C., Vidrich A., Czaja A. J. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology. 1995 Apr;108(4):1159–1166. doi: 10.1016/0016-5085(95)90215-5. [DOI] [PubMed] [Google Scholar]
  43. Toda G., Zeniya M., Watanabe F., Imawari M., Kiyosawa K., Nishioka M., Tsuji T., Omata M. Present status of autoimmune hepatitis in Japan--correlating the characteristics with international criteria in an area with a high rate of HCV infection. Japanese National Study Group of Autoimmune Hepatitis. J Hepatol. 1997 Jun;26(6):1207–1212. doi: 10.1016/s0168-8278(97)80453-9. [DOI] [PubMed] [Google Scholar]
  44. Toh B. H. Anti-cytoskeletal autoantibodies: diagnostic significance for liver diseases, infections and systemic autoimmune diseases. Autoimmunity. 1991;11(2):119–125. doi: 10.3109/08916939109035142. [DOI] [PubMed] [Google Scholar]
  45. Treichel U., McFarlane B. M., Seki T., Krawitt E. L., Alessi N., Stickel F., McFarlane I. G., Kiyosawa K., Furuta S., Freni M. A. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology. 1994 Sep;107(3):799–804. doi: 10.1016/0016-5085(94)90129-5. [DOI] [PubMed] [Google Scholar]
  46. Yamamoto A. M., Cresteil D., Homberg J. C., Alvarez F. Characterization of anti-liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology. 1993 Jun;104(6):1762–1767. doi: 10.1016/0016-5085(93)90657-x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES